Financial Data and Key Metrics Changes - Revenues in Q3 2025 were $1.9 million, down from $2.4 million in Q3 2024, impacted by the expiration of the National Quantum Initiative [10] - Gross margins decreased to 21% in Q3 2025 from 51% in Q3 2024, attributed to the composition of revenue and pricing variability [10] - Total operating expenses increased to $21 million in Q3 2025 from $18.6 million in the same period of the prior year, due to salary increases, new hires, and higher stock-based compensation [11] - GAAP net loss for Q3 2025 was higher than in Q3 2024, primarily due to a non-cash change in the fair value of derivative warrant and earn-out liabilities [12] - As of September 30, 2025, the company had approximately $558.9 million in cash and equivalents, with no debt, and this increased to approximately $600 million by November 6, 2025 [12] Business Line Data and Key Metrics Changes - The company announced purchase orders totaling approximately $5.7 million for two 9-qubit Novera quantum computing systems, which are upgradable [5] - A three-year, $5.8 million contract from the Air Force Research Laboratory (AFRL) was secured to advance superconducting quantum networking [6] Market Data and Key Metrics Changes - The expiration of the National Quantum Initiative and its pending reauthorization in the U.S. Congress impacted revenue, with future sales dependent on its renewal [10] - The company is engaged with various academic and government sectors to enhance quantum computing capabilities, including collaborations with Montana State University and the Center for Development of Advanced Computing [7][8] Company Strategy and Development Direction - The company aims to deliver a 150-plus qubit system by the end of 2026 and a 1,000-plus qubit system by the end of 2027, with anticipated gate fidelity improvements [4][5] - The strategy includes deepening support for quantum computing capabilities in academic and government sectors and integrating with NVIDIA's NVLink for AI supercomputer quantum integration [8] - The company plans to open an Italian subsidiary to accelerate business opportunities in the region [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future sales from recent contracts and collaborations, which are expected to benefit revenue in Q4 2025 and into 2026 [10] - The management acknowledged challenges in achieving long-range coupling and error correction, which are critical for future milestones [17] - The company is optimistic about being selected for phase B of the DARPA Quantum Benchmarking Initiative project in the coming months [18] Other Important Information - The company is exploring options for potential M&A to accelerate its roadmap, although it believes it can execute its current plans organically [47][48] - The company is considering significant capital expenditures for upgrading its chip fabrication facility in the future [56][60] Q&A Session Summary Question: Can you talk about DARPA phase B and the feedback received? - Management noted that while they were not selected for phase B, constructive feedback was received regarding error correction and long-range coupling, which are important for future milestones [16][17] Question: What is the comfort level for achieving 99% fidelity by 2027? - Management expressed confidence in achieving 99.8% fidelity with 1,000 qubits by the end of 2027, emphasizing the importance of error correction [20][22] Question: Will the 150-qubit and 1,000-qubit systems use chiplet-based approaches? - The company plans to use 9-qubit chiplets for the 150-qubit system and 36-qubit chiplets for the 1,000-qubit system [27] Question: How will revenue recognition work for the Novera system sales? - Revenue for the two Novera systems will be recognized upon shipment, expected in Q1 and Q2 of 2026 [31] Question: What is the expected gross margin profile moving forward? - Management indicated that while gross margins were lower in Q3, future sales, particularly from Novera, are expected to have better margins [64] Question: How does the recent funding for the National Quantum Initiative affect the business? - Management noted that the reinstatement of funding to $625 million over five years is a positive step, although discussions for higher funding amounts are ongoing [81][82]

Financial Data and Key Metrics Changes - Total consolidated revenues for Q3 2025 were $45.1 million, reflecting a 1% year-over-year increase compared to pro forma Q3 2024 [23] - Net loss attributable to common stockholders was $33.2 million, a year-over-year decline of approximately $700,000 or 2%, with a net loss per share of $2.61, improving by $3.28 per share or 56% compared to Q3 2024 [31] - Non-GAAP adjusted net loss attributable to common stockholders for Q3 was $7.2 million, representing an improvement of around $18 million or 71% versus the comparable period in 2024 [32] Business Line Data and Key Metrics Changes - Hospitality revenues declined 4% year-over-year in Q3, primarily due to lower revenues at the Tin Building and certain legacy standalone restaurants [24] - Same-store hospitality revenue rose 11%, driven by the success of the Long Club and the strong launch of Dutano [25] - Entertainment segment revenues decreased 5% year-over-year, mainly due to hosting seven fewer concerts at the Rooftop at Pier 17 compared to the prior year [26] Market Data and Key Metrics Changes - International visitation to New York City remains below pre-pandemic levels, currently at about 90% of 2019 volume, while domestic travel remains resilient [5] - Total New York City visitation is projected to reach almost 65 million visitors in 2025, surpassing 2024 levels and approaching pre-pandemic visitation levels [6] - The Manhattan office market has shown strength, with leasing activity exceeding pre-COVID levels, particularly in financial services, technology, and media industries [6] Company Strategy and Development Direction - The company aims to refine its focus and priorities to stabilize and optimize operating models, emphasizing financial discipline and thoughtful capital deployment [4] - Plans include reinvestment into existing assets to improve space utilization and drive customer engagement, while also seeking opportunistic growth in real estate-driven hospitality and entertainment platforms [5] - The company is committed to enhancing the Seaport as a cultural and experiential destination, leveraging marquee events to drive visitation and awareness [39] Management's Comments on Operating Environment and Future Outlook - Management noted that the New York City market presents a mixed picture, with challenges in international tourism but resilience in domestic travel [5] - The company is optimistic about the performance of new hospitality concepts and events, which are expected to drive customer spending and engagement [12][16] - Management expressed confidence in the sale of 250 Water Street, which is expected to positively impact cash burn and eliminate associated interest expenses [10] Other Important Information - The company completed several technology initiatives, including centralizing point-of-sale and procurement systems across hospitality businesses, enhancing financial visibility and reporting accuracy [13] - The sale of 250 Water Street is expected to close by December 15, with an increased sale price of $152 million [10] - General and administrative expenses during the quarter were $18 million, reflecting a year-over-year reduction of 2% [30] Q&A Session Summary Question: What are the biggest levers to drive profitability? - Management highlighted the importance of getting tenants open and operational, focusing on operational efficiencies, and filling remaining vacancies as key drivers for profitability [35] Question: Can you discuss the demand for prospective spaces? - Management noted strong demand for restaurant space and is focusing on finding the right partners and experiences for the community [36] Question: What is the timing for opening new tenants? - Management anticipates that velocity will pick up in the back half of the year, with several openings expected before Meow Wolf [38] Question: What are the expectations for the Tin Building's break-even in 2026? - Management stated that they are not in a position to provide forward guidance on the Tin Building's performance in 2026 but will outline plans in the next earnings call [41] Question: What are the capital expenditures expected for Q4? - Management indicated that capital expenditures for Q4 will be somewhat light, with a ramp-up expected in the first half of 2026 [45]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $33.3 million, a 19% increase from $27.9 million in Q3 2024, primarily driven by $5.5 million in licensing revenue and $576,000 in additional biologics revenue, despite a 6% decline in hardware product revenue [13][8][4] - Gross margin improved to 66.1% in Q3 2025 from 58.4% in Q3 2024, attributed to a favorable sales mix and greater scale [13] - Net income for Q3 2025 was $1.3 million, compared to a net loss of $5 million in the same period last year [16] - Adjusted EBITDA for Q3 2025 was $4.5 million, a significant improvement from an adjusted EBITDA loss of approximately $1 million in Q3 2024 [16] Business Line Data and Key Metrics Changes - The biologics product family, the core business, grew by 4% year-over-year, which was below long-term growth expectations [8] - The company is focusing on higher-margin biologics and in-house manufacturing to improve quality and control costs, with plans to drive top-line growth in the orthobiologics business [9] Market Data and Key Metrics Changes - The company anticipates closing the sale of non-core assets for $19.2 million, which will enhance focus on the core biologics business and strengthen financial position [5][6] - The anticipated revenue from the sold business was approximately $23.5 million, which was modestly unprofitable on a standalone basis [6] Company Strategy and Development Direction - The company is shifting focus back to driving top-line growth in orthobiologics after achieving self-sustainability and positive cash flows [9] - New product launches include CollagenX, which is designed for surgical wound closure and complements the existing orthobiologics product line [10] - The company is well-positioned to grow in the surgical repair and wound care markets, supported by positive feedback from surgeons on recent innovations [11] Management's Comments on Operating Environment and Future Outlook - Management reiterated 2025 revenue guidance of $131 million to $135 million, reflecting an 11%-15% growth over 2024 revenue [11][12] - The company expects to provide initial 2026 revenue guidance with Q4 results in March of next year [12] Other Important Information - The company has $10.6 million in cash and cash equivalents, with net accounts receivable of $25.6 million and inventory of $40.7 million as of September 30, 2025 [17] Q&A Session Summary Question: Plans for investment in the commercial organization - Management indicated plans to increase the number of sales representatives from four to eight by the end of the year, with expectations to add four more in 2026, focusing on strategic areas [19][21] Question: Growth expectations for the orthobiologics business in 2026 - Management expects low double-digit growth for the orthobiologics business in 2026, while hardware growth remains uncertain [22] Question: Insights on new product launches at NAS - Management highlighted three key products: a new growth factor product, an advanced DBM called Trivium, and the recently launched CollagenX, all of which are expected to enhance the product portfolio [25][26] Question: Year-over-year growth in orthobiologics - The orthobiologics business experienced a 4% growth, driven by the stem cell and amnio product lines, while older demineralized bone products faced declines [30][33] Question: Impact of amnio product pricing changes - The company is well-positioned to benefit from the new pricing structure for amnio products, leveraging strong hospital contracts [38] Question: Plans for distributing CollagenX - Management sees significant potential for CollagenX in various markets, leveraging the existing platform technology acquired through previous acquisitions [40][41]

Summary of Immunome FY Conference Call (November 11, 2025) Company Overview - **Company**: Immunome (NasdaqCM:IMNM) - **Focus**: Standalone pure-play cancer company specializing in targeted therapies, including antibody-based therapies, radioligands, and small molecules [1][1] Key Points on Varegacestat - **Asset**: Varegacestat, a gamma-secretase inhibitor, is nearing completion of phase three clinical trials for desmoid tumors [2][2] - **Market Opportunity**: The commercial opportunity in desmoid tumors is substantial, with approximately 1,650 new cases per year in the US and a prevalence of about 30,000 [9][15] - **Differentiation**: Varegacestat is expected to differentiate itself from Ogsivo (nirogacestat) due to better efficacy and dosing convenience (once daily vs. twice daily) [10][10][22][22] - **Phase 2 Data**: Phase 2 data indicated a significant improvement over nirogacestat, with a median tumor volume reduction that was 20-25% better [10][10] - **Regulatory Readiness**: The company is well-prepared for regulatory submission and product launch, with a strong team in place [14][14] Clinical Trial Insights - **Enrollment**: Enrollment for the phase 3 trial was completed in February 2024, with data expected to be released soon [11][11] - **Data Monitoring**: A Data Safety Monitoring Board (DSMB) has been overseeing the trial, ensuring safety and compliance [24][24] - **Comparison with Competitors**: The trial design and patient enrollment criteria are nearly identical to those used in SpringWorks' trial for nirogacestat, which is considered the gold standard [17][18] ADC Development - **ROR1 ADC**: Immunome is developing an antibody-drug conjugate (ADC) targeting ROR1, utilizing a proprietary payload (HC74) [27][27] - **Technology Differentiation**: The ADC aims to improve upon existing technologies by addressing common resistance pathways and enhancing permeability for better therapeutic activity [32][32][33][33] - **Future Pipeline**: The company plans to introduce additional ADCs in 2026 and 2027, with a focus on high internalization antibodies [34][34] Market Potential - **Revenue Potential**: A drug targeting 3,000 patients could generate over a billion dollars in revenue, with a significant number of treatable patients available in the US and Europe [15][15] - **Patient Compliance**: The once-daily dosing of Varegacestat is expected to improve patient compliance compared to competitors [10][10] Conclusion - Immunome is positioned to capitalize on the growing market for targeted cancer therapies, with a strong focus on developing innovative treatments that offer significant advantages over existing options. The upcoming data release for Varegacestat is highly anticipated and could be a pivotal moment for the company.

Financial Performance - Telecom Argentina's 9M25 adjusted EBITDA reached US$41 billion, a 73% increase compared to 9M24[12] - The company's 9M25 revenues showed an EBITDA margin of 305%, compared to 288% in 9M24[12] - Service revenues increased by 5% to P$3,860 million in 9M25, compared to P$3,679560 million in 9M24[24] - The company's 9M25 CAPEX was US$615 million, focused on mobile and FTTH network deployment[12] - Free cash flow generation for 9M25 was US$402 million[76] Operational Highlights - The company has a leading position in the market with 32 million Pay TV subscribers and 203 million Mobile subscribers[13] - Broadband subscribers increased to 41 million[14] - Personal Pay onboarded approximately 44 million clients[14] - Mobile ARPU increased by 10% for TEO and 5% for TMA[26] - Broadband ARPU increased by 3% for TEO and 14% for TMA[26] - Pay TV ARPU increased by 2% for TEO and 19% for TMA[26] Debt and Leverage - Net debt to estimated proforma EBITDA LTM9M25 was 19x[12] - Total funds raised in 2025 amounted to US$27 billion[92]

Financial Data and Key Metrics Changes - The company reported record quarterly revenue of $13.5 million for Q3 2025, a 29% increase compared to $10.5 million in the same period last year [5][15] - Gross profit for the quarter was $10.2 million, up from $7.7 million in the prior year, maintaining a gross margin of 75% [16] - Operating profit increased to approximately $1.3 million from $0.3 million year-over-year, with adjusted EBITDA rising to $2 million from $1.1 million [16][18] - The company ended the quarter with $70.7 million in cash and cash equivalents, an increase of $1.1 million from the previous year [17] Business Line Data and Key Metrics Changes - The company shipped 90 deep TMS systems during the quarter, representing a 43% increase year-over-year, bringing the total install base to over 1,600 systems [5][15] - Approximately 70% of recent customer engagements were structured as lease agreements, indicating a strong transition to this sales model [6][7] Market Data and Key Metrics Changes - Remaining performance obligations under existing customer agreements grew to $65 million, a 37% year-over-year increase, providing strong visibility into future revenues [17] - The company is seeing strong demand momentum, reflected in a book-to-bill ratio of 1.3x for the quarter [8] Company Strategy and Development Direction - The company focuses on three key pillars for long-term growth: elevating market awareness of deep TMS, advancing the R&D roadmap, and broadening patient access through global extension and health system integration [9] - Recent FDA approval for an accelerated treatment protocol for major depressive disorder (MDD) is expected to enhance the appeal of deep TMS to prospective patients [10] - The company is pursuing minority equity investments in mental health providers to generate shareholder value and expand market awareness [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong execution of the business model and improved visibility into the remainder of the year [5][6] - The company raised its revenue guidance for the full year 2025 to a range of $51 to $52 million, reflecting a year-over-year growth rate of 24% to 27% [18] Other Important Information - The company announced a virtual investor and analyst day on December 1 to discuss operational, clinical, regulatory, and financial progress [14] - The company remains debt-free, providing significant flexibility for strategic growth initiatives [17] Q&A Session Summary Question: Can you discuss the accelerated protocol and its current treatments? - The accelerated protocol shortens the acute phase from four weeks to six days, increasing treatment frequency to five sessions per day, which is driving demand for the company's growth [21] Question: What can be expected regarding minority equity investments? - The company has a pipeline of minority investments and aims to sign at least one more by the end of the year, with promising opportunities for 2026 [22] Question: Update on NeuroLife's activities in Japan and the EU? - The company anticipates FDA clearance for NeuroLife's device by the end of the year, which will enable distribution through various channels [23] Question: Insights on system placements from minority partners? - Minority investments are expected to lead to the opening of 10 to 15 new clinics annually, with early investments showing over 50% growth in utilization rates [28][29] Question: Plans for altering metrics reporting? - The company plans to provide more granularity on metrics, including system shipments and performance of minority investments, during the analyst day [35] Question: State of international business and growth expectations? - The company expects strong growth from Asia-Pacific and Europe, particularly in Japan, China, and major European markets [36][37]

Financial Data and Key Metrics Changes - Consolidated third quarter 2025 revenue was $152.5 million, down from $171.8 million in the prior year, primarily due to softening customer demand in North America [11] - Adjusted EBITDA for the third quarter was $4.6 million, compared to $4.3 million in the prior year, with adjusted EBITDA margins increasing to 3.0% from 2.5% [11] - Net loss for the quarter was $6.8 million, or a loss of $0.20 per diluted share, compared to a net loss of $0.9 million, or a loss of $0.03 per diluted share in the prior year [12] - Free cash flow from continuing operations was negative $3.4 million, down from positive $17.1 million in the prior year [12] Business Line Data and Key Metrics Changes - Global ceiling segment revenues were $68.7 million, a decrease of 10% year-over-year, but adjusted operating income increased to $2.9 million [13][14] - Global electrical systems segment revenues increased by 6% to $49.5 million, with adjusted operating income rising to $1.4 million [14][15] - Trim systems and components revenues decreased by 29% to $34.3 million, with an adjusted operating loss of $0.3 million compared to profits of $4.1 million in the prior year [16][17] Market Data and Key Metrics Changes - ACT Research forecasts a 28% decline in North American Class 8 heavy truck build volumes for 2025, with a further decline of 14% in 2026 [18] - The construction market is expected to decline by 5-10%, while agriculture markets are projected to decrease by 5-15% due to higher interest rates and lower commodity prices [19] Company Strategy and Development Direction - The company is focused on driving operational efficiencies and reducing costs, including right-sizing manufacturing footprints and optimizing production capacity in regions with better demand [6][9] - The global electrical systems segment is a key area for growth, with expectations for sales to increase in the high single-digit to low double-digit percentage range in 2026 [20][21] - The company is actively pursuing new business opportunities in autonomous vehicles and infrastructure markets to enhance revenue and margin growth [21][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged broader market and macroeconomic uncertainties but expressed confidence in the company's ability to enhance shareholder value through operational improvements and new business wins [9][28] - The company expects to generate at least $30 million in free cash flow for the full year, which will be used to pay down debt [26] Other Important Information - The company has generated $25 million in free cash flow year-to-date, up $14 million from the previous year, driven by improved working capital performance [6] - The net leverage ratio at the end of the third quarter was 4.9 times, slightly up from 4.8 times at the end of the second quarter [13] Q&A Session Summary Question: How much more can be achieved in efficiency improvements before needing to increase CapEx? - Management indicated that there are still opportunities for further operational efficiency improvements without significantly impacting the ability to respond to market changes [34][35] Question: Why is there a larger reduction in adjusted EBITDA compared to revenue guidance? - The larger reduction in adjusted EBITDA is primarily due to deleveraging and the fixed cost nature of the North American Class 8 business, which has been significantly impacted by reduced volumes [38] Question: Can the new electrical system products offset declines in the Class 8 business in 2026? - Management expects that the ramp-up of new business in the electrical systems segment will help offset the anticipated downturn in the Class 8 business [39] Question: When will the ramp of new programs in electrical systems reach full annualized rates? - The ramp in volume is expected to start in the second half of 2026, with full annualized rates anticipated in late 2027 or 2028 [44][45] Question: What is the status of tariff negotiations with customers and suppliers? - Management has engaged with customers to provide data on tariff impacts and has made progress in negotiations for price adjustments and mitigation strategies [50][51]

Natural Gas Services Group (NYSE:NGS) Q3 2025 Earnings Call November 11, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to the Natural Gas Services Group Incorporated Quarter Three Earnings Call. I would now like to turn the call over to Ms. Hannah Delgado. Please begin.Speaker1Thank you, Luke, and good morning, everyone. Before we begin, I would like to remind you that during the course of this conference call, the company will be making forward looking statements within the meani ...

ASM: TSX/NYSE American www.avino.com A Clear Path to Transformational Growth November 2025 Precious Metals Summit - Zurich A CLEAR PATH TO TRANSFORMATIONAL GROWTH The Avino Mine Property ASM: TSX/NYSE American www.avino.com A Clear Path to Transformational Growth 2 CAUTIONARY DISCLAIMER: FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking information" and "forward-looking statements" (together, the "forward looking statements") within the meaning of applicable securities laws and the Unit ...

Ambac Financial Group (NYSE:AMBC) Q3 2025 Earnings Call November 11, 2025 08:30 AM ET Speaker3Ladies and gentlemen, good morning and welcome to the Octave Specialty Group's third quarter 2025 earnings call. At this time, all participants are in listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please signal the operator by pressing star zero on your telephone keypad. As a reminder, this conference is ...